| Business Summary | | Cel-Sci
Corporation
is
involved
in
the
research
and
development
of
several
drugs
and
vaccines.
The
Company's
first
and
main
product,
MULTIKINE,
is
being
developed
for
the
treatment
of
head
and
neck
cancer.
The
Company
is
also
conducting
studies
with
MULTIKINE
in
prostate
cancer
patients
and
is
planning
to
start
a
cervical
cancer
study
by
the
first
quarter
of
2001.
The
Company's
heteroconjugate
technology,
L.E.A.P.S.
(Ligand
Epitope
Antigen
Presentation
System),
has
potential
applications
in
the
development
of
treatments
and/or
vaccines
against
various
diseases.
The
Company
also
has
completed
Phase
II
human
clinical
trials
of
a
preventive
vaccine
against
HIV
infection. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | CVM
is
involved
in
the
research
and
development
of
certain
drugs
and
vaccines
using
the
Company's
proprietary
cell
culture
technologies.
CVM's
first
product,
MULTIKINE,
is
being
tested
to
determine
if
it
is
effective
in
improving
the
immune
response
of
cancer
patients.
For
the
nine
months
ended
6/01,
revenues
increased
84%
to
$551
thousand.
Net
loss
rose
22%
to
$8.2
million.
Revenues
reflect
interest
accrued
on
investments.
Higher
loss
reflects
clinical
trial
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Geert Kersten, 41 CEO,
Sec., Treasurer, Director | $333K | $137K | Maximilian De Clara, 70 Pres,
Director | 969K | 1.4M | Michael Luecke, 58 Sr.
VP of Bus. Devel. | 159K | 44K | Patricia Prichep, 49 Sr.
VP of Operations | 124K | 90K | Eyal Talor, Ph.D., 44 Sr.
VP of Research and Manufacturing | 162K | 275K | Dollar
amounts are as of 30-Sep-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|